Analyzing the Recent Advancements in Gastrointestinal Therapeutics Industry

The diagnosis, treatment, and rehabilitation of patients suffering from gastrointestinal disorders is one of the main focus areas of the healthcare sector. In the past few years, several advancements have taken place in gastrointestinal therapeutics sector in the form of drug discovery and targeted therapies.

Recent advancements in gastrointestinal therapeutics

A majority of the research in gastrointestinal therapeutics industry is centered on treatment of ailments such as gastric cancer, Crohn’s disease, and pancreatic cancer. As far as gastric cancer is concerned, a reputed institute called New York-Presbyterian/Weill Cornell Medicine has come up with a targeted treatment approach. Called zolbetuximab, the targeted therapy when given to the patient in combination with chemotherapy has been extremely effective in killing cancer cells. Similarly, the same institute has developed a drug named Ustekinumab for the treatment of Crohn’s disease. The drug has shown the capability to target both interleukin-12 (IL-12) and interleukin-23 (IL-23) cytokines, effectively. In the case of pancreatic cancer, the research is primarily focused on improving the screening and treatment capabilities for early detection of cancer. Many experts in this field have suggested the use of genetics including strategies such as gene replacement and gene enhancement.

Future growth opportunities to the industry

The gastrointestinal therapeutics market is expected to be primarily driven by the rising incidence of chronic gastrointestinal ailments such as inflammatory bowel disease (IBD), gastrointestinal cancers, and gastroesophageal reflux disease (GERD). Additionally, the growing proportion of geriatric population across the globe is predicted to help the market to surge ahead in the near future. Along with this, advancements in the field of the healthcare sector are widening the scope of the industry. These factors are predicted to help the market to grow at a CAGR of 5% during the 2023-2032 period.

The global gastrointestinal therapeutics industry has been segmented on the lines of drug class, application, and distribution channel. On the basis of drug class, the biologics segment is expected to experience an absolute growth revenue of $12,450.31 million during the 2023-2032 period. At the same time, the H2 antagonists and laxatives segment is anticipated to gather an absolute revenue of $1,827.38 million during the same period. Regional analysis of the market reveals that the industry in China is projected to have the highest CAGR of 7.4% from 2023 to 2032.

In addition to the aforementioned factors, product launches by leading biomedical companies have created new growth opportunities for the market. For instance, in October 2020, Evoke Pharma, Inc., and EVERSANA™ announced the launch of Gimoti™, a nasal spray for patients suffering from acute diabetic gastroparesis. Such product launches have helped the market to expand its operations across the globe and meet the demands of the healthcare sector in a comprehensive manner.

The global gastrointestinal therapeutics industry, to summarize, has witnessed huge advances in recent times with a special focus on treating gastrointestinal cancers. Huge growth of the market in China and product launches by major pharmaceutical companies have also played a massive role in strengthening the position of this industry

Related Post